- Home
- IGC vs LFWD Comparison
IGC vs LFWD Comparison
Compare IGC & LFWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGC
- LFWD
- Stock Information
- Founded
- IGC 2005
- LFWD 2001
- Country
- IGC United States
- LFWD Israel
- Employees
- IGC N/A
- LFWD N/A
- Industry
- IGC Biotechnology: Pharmaceutical Preparations
- LFWD
- Sector
- IGC Health Care
- LFWD
- Exchange
- IGC Nasdaq
- LFWD NYSE
- Market Cap
- IGC 28.4M
- LFWD 32.4M
- IPO Year
- IGC N/A
- LFWD 2014
- Fundamental
- Price
- IGC $0.35
- LFWD $3.09
- Analyst Decision
- IGC Strong Buy
- LFWD Strong Buy
- Analyst Count
- IGC 2
- LFWD 1
- Target Price
- IGC $3.63
- LFWD $13.00
- AVG Volume (30 Days)
- IGC 371.2K
- LFWD 41.3K
- Earning Date
- IGC 08-08-2024
- LFWD 08-15-2024
- Dividend Yield
- IGC N/A
- LFWD N/A
- EPS Growth
- IGC N/A
- LFWD N/A
- EPS
- IGC N/A
- LFWD N/A
- Revenue
- IGC $1,062,000.00
- LFWD $23,277,000.00
- Revenue This Year
- IGC $0.59
- LFWD $124.19
- Revenue Next Year
- IGC $13.01
- LFWD $44.50
- P/E Ratio
- IGC N/A
- LFWD N/A
- Revenue Growth
- IGC N/A
- LFWD 313.30
- 52 Week Low
- IGC $0.25
- LFWD $3.00
- 52 Week High
- IGC $0.91
- LFWD $9.10
- Technical
- Relative Strength Index (RSI)
- IGC 35.05
- LFWD 36.38
- Support Level
- IGC $0.33
- LFWD $3.07
- Resistance Level
- IGC $0.37
- LFWD $3.42
- Average True Range (ATR)
- IGC 0.02
- LFWD 0.16
- MACD
- IGC -0.00
- LFWD -0.02
- Stochastic Oscillator
- IGC 19.90
- LFWD 5.48
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
About LFWD REWALK ROBOTICS LTD
Rewalk Robotics Ltd is a medical device company that designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering functional and health benefits in clinical settings as well as in the home and community. Its product offerings are the ReWalk Personal and ReWalk Rehabilitation Exoskeleton devices for individuals with spinal cord injury. It operates through markets in the United States and Europe with some lesser sales in Asia, the Middle East and South America.